Jiangsu HengRui Medicine Co., Ltd.: Diabetes Mellitus, Type 2 trials

The registry lists 54 Diabetes Mellitus, Type 2 studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 25Phase 2 15Phase 3 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of HRS-4729 Injection in Participants With Type 2 DiabetesNot yet recruitingNCT07843862Phase 2
• A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple DosesNot yet recruitingNCT07841860Phase 1
• A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal ImpairmentRecruitingNCT07807059Phase 1
• Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinRecruitingNCT07060456Phase 3
• A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 DiabetesRecruitingNCT07032688Phase 1
• A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy ParticipantsNot yet recruitingNCT06506175Phase 1
• A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic AgentsActive, not recruitingNCT07472725Phase 2
• A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic DrugsActive, not recruitingNCT07018453Phase 2
• Mass Balance Study of [14C]HRS9531 in Healthy Male SubjectsCompletedNCT06855147Phase 1
• A Clinical Study of Mass Balance of [14C]HRS-7535CompletedNCT06819488Phase 1
• Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsCompletedNCT06688123Phase 2
• A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and ExerciseCompletedNCT06672172Phase 3
• the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneCompletedNCT06650007Phase 3
• The Experiment of Noiiglutide Injection in Type 2 Diabetes PatientsCompletedNCT06649773Phase 3
• A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesCompletedNCT06649344Phase 3
• A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminCompletedNCT06589765Phase 3
• Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy HumanCompletedNCT06495931Phase 1
• Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy SubjectsCompletedNCT06422039Phase 1
• Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 DiabetesCompletedNCT06415214Phase 2
• Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.CompletedNCT06393348Phase 2
• A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy SubjectsCompletedNCT06246175Phase 1
• Assessment of Gastric Emptying by SHR20004 in Healthy SubjectsCompletedNCT06137469Phase 1
• Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsCompletedNCT05966272Phase 2
• A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes MellitusStatus unknownNCT05759897Phase 2
• To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.CompletedNCT05702073Phase 3
• To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsCompletedNCT05699408Phase 3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusCompletedNCT05516966Phase 1
• Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy SubjectsCompletedNCT05415644Phase 1
• A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesStatus unknownNCT05333835Phase 2
• A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy VolunteersStatus unknownNCT05120219Phase 1
• A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese SubjectsStatus unknownNCT05108350Phase 1
• Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 DiabetesActive, not recruitingNCT05054842Phase 3
• Pharmacokinetics of HR17031 Injection in Healthy SubjectsCompletedNCT05031871Phase 1
• Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin MonotherapyStatus unknownNCT04667143Phase 3
• A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral AntidiabeticsCompletedNCT04663282Phase 2
• Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 DiabetesStatus unknownNCT04390295Phase 3
• A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.CompletedNCT03848793Phase 2
• Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal InsufficientStatus unknownNCT03159832Phase 1
• Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 DiabetesStatus unknownNCT03159052Phase 3
• The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes PatientsStatus unknownNCT02822534Phase 1
• The Drug -Drug Interaction of SP2086 and GlyburideCompletedNCT02815787Phase 1
• The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366377Phase 1
• The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366351Phase 1
• The PK/PD Study of Multiple Dose of SHR3824 in Healthy VolunteersCompletedNCT02361138Phase 1
• The PK/PD Study of Single Dose of SHR3824 in Healthy VolunteersCompletedNCT02356224Phase 1
• Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus PatientsCompletedNCT02346175Phase 1
• Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT01984489Phase 2
• A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 DiabetesCompletedNCT01976858Phase 1
• A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesStatus unknownNCT01970046Phase 3
• Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 DiabetesStatus unknownNCT01970033Phase 3
• A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 DiabetesCompletedNCT01969357Phase 2
• Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT01969318Phase 2
• A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 DiabetesCompletedNCT01965509Phase 2
• A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 DiabetesCompletedNCT01965496Phase 1